Florian Clatot
A5066607014- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Head and Neck Cancer Studies
- Advanced Breast Cancer Therapies
- Glioma Diagnosis and Treatment
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Reproductive Biology and Fertility
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Ovarian cancer diagnosis and treatment
- Brain Metastases and Treatment
- Colorectal and Anal Carcinomas
- Nutrition and Health in Aging
- Radiopharmaceutical Chemistry and Applications
- Cancer Risks and Factors
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- Immune cells in cancer
- Genetic factors in colorectal cancer
- Ovarian function and disorders
- Central Venous Catheters and Hemodialysis
Centre Henri Becquerel
2016-2025
Inserm
2015-2025
Centre Virchow-Villermé
2015-2024
Université de Rouen Normandie
2009-2024
Normandie Université
2017-2024
Laboratoire National Henri Becquerel
2020-2024
Centre Hospitalier Universitaire de Rouen
2023
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2014-2022
Institute for Research and Innovation in Biomedicine
2020
Université Libre de Bruxelles
2017-2019
Approximately 25–35% of patients with diffuse large B-cell lymphoma (DLBCL) are older than 70 years. The aim this study was to investigate the prognostic impact depletion skeletal muscle (sarcopenia) in elderly DLBCL. This retrospective analysis included 82 DLBCL years and treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin, prednisone) or R-miniCHOP. Sarcopenia measured by stored computed tomography (CT) images at L3 level baseline. surface muscular tissues selected according...
Approximately 30% of DLBCL patients are older than 70 yr. This study evaluated the prognostic impact a cachexia score (CS) including fat tissue loss (adipopenia) and sarcopenia as assessed by computed tomography (CT scan) in elderly treated with chemotherapy rituximab (R).This retrospective analysis included 80 yr R-CHOP or R-miniCHOP. Skeletal muscle (SM) visceral (V) subcutaneous (S) adipose (A) tissues were measured analysing CT images at third lumbar (L3) level.The median age was 78...
The direct comparison of CA19.9, circulating tumour cells (CTCs) and DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis solid pancreatic tumours (SPTs).We included 68 patients with a SPT referred EUS-FNA. CTCs were analysed size-based platform ctDNA digital PCR. sensitivity, specificity, negative positive predictive values evaluated each marker their combination.SPTs corresponded to 58 malignant (52 adenocarcinoma (PA) 6...
Young women with germline BRCA mutations have unique reproductive challenges. Pregnancy after breast cancer does not increase the risk of recurrence; however, very limited data are available in patients mutations. This study investigated impact pregnancy on outcomes mutations.This is an international, multicenter, hospital-based, retrospective cohort study. Eligible were diagnosed between January 2000 and December 2012 invasive early at age ≤ 40 years harbored deleterious Primary end points...
We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo CRT in 96 patients with unresected locally advanced squamous cell carcinoma of the head neck (LA SCCHN).Patients were randomised 1:1 to 200 mg/day (days 1-14 21-day cycle for 3 cycles), or matched placebo, (cisplatin 100 mg/m2 every weeks cycles conventional fractionated high-dose...
Importance Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy survivors included limited data BRCA carriers. Objective To investigate cumulative incidence disease-free survival young are Design, Setting, Participants International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The...
// Florian Clatot 1,2,3 , Anne Perdrix 3,4 Laetitia Augusto 1 Ludivine Beaussire 3,5 Julien Delacour Céline Calbrix 4 David Sefrioui 3,5,6 Pierre-Julien Viailly 2 Michael Bubenheim 7 Cristian Moldovan Cristina Alexandru Isabelle Tennevet Olivier Rigal Cécile Guillemet Marianne Leheurteur Sophie Gouérant Camille Petrau 1,3 Jean-Christophe Théry 1,5 Jean-Michel Picquenot 1,2,4 Corinne Veyret Thierry Frébourg 5 Fabrice Jardin Nasrin Sarafan-Vasseur 3,5,* and Frédéric Di Fiore 1,3,5,6,*...
Acquired estrogen receptor gene (ESR1) mutations have been recently reported as a marker of resistance to aromatase inhibitors in hormone positive metastatic breast cancer. We retrospectively considered seven patients treated for cancer with available samples from the primary tumor before any treatment, cryopreserved metastasis removed during progression and concomitant plasmas. All these were disease after previous exposure at least 6 months, assessed ESR1 detection circulating DNA. For...
Lipophilic drugs, such as taxanes, have a high affinity for adipose tissue and resulting higher volume of distribution. Here, we reanalyzed clinical trial data to investigate whether the efficacy docetaxel-based chemotherapy differs from non-docetaxel-based in patients with breast cancer according their baseline body mass index (BMI).We retrospectively analyzed all adjuvant BIG 2-98 (ClinicalTrials.gov identifier: NCT00174655; N = 2,887) comparing non-docetaxel- docetaxel-containing...
Introduction The combination of a CDK4/6 inhibitor with an aromatase (AI) has recently become the gold standard for AI-sensitive first line treatment oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. However, most patients receiving this will ultimately progress and require further therapies. Several studies have demonstrated that onset ESR1 gene mutation lead to AIs resistance in setting. mutations can be detected circulating tumour DNA (ctDNA) using digital...
Abstract Background: ESR1 mutations are known drivers of resistance to first line aromatase inhibitors (AI)-based therapy in hormone receptor-positive (HR+) HER2- metastatic breast cancer (mBC) patients (pts), but their clinical actionability remains unknown. The randomized phase 3 PADA-1 trial aimed at evaluating the benefit associated with a switch fulvestrant-palbociclib upon detection rising mutation blood (bESR1mut) HR+ mBC pts treated by AI-palbociclib.. Methods: (NCT03079011),...
6014 Background: EGFR is a known oncogenic driver in HNSCC, and the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) expressed on cancer stem cells, including HNSCC. Petosemtamab human, common light chain, IgG1 bispecific antibody with ADCC-enhanced activity, targeting LGR5. In dose escalation part of phase 1/2 study, recommended 2 (RP2D) was determined to be 1500 mg every weeks (Q2W). Interim data petosemtamab monotherapy at RP2D 2L/3L HNSCC led 37.2% overall response rate...
Background: Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying deleterious germline BRCA mutation ovarian reserve measured by anti-müllerian hormone (AMH) levels young breast cancer patients receiving (neo)adjuvant cyclophosphamide- anthracycline-based chemotherapy. Methods: This is biomarker analysis including (≤ 40 years) early with known mutational status available prospectively collected frozen plasma samples before after Chemotherapy consisted...
1010 Background: The question of which is the best endocrine partner to CDK4/6 inhibitors in first line for ER+ HER2- metastatic breast cancer (MBC) remains open. ESR1 mutations might be paramount importance, as they confer resistance AI but not SERD. In pts treated with palbociclib-AI combination (PADA-1 trial, NCT03079011), we investigated ESR1mut detection rate at inclusion, prior any therapy, and their prognostic impact. Methods: PADA-1 phase 3 trial (NCT03079011, UCBG-GINECO) evaluates...
It is well established that cancer and its treatment, whether by chemotherapy, radiotherapy, hormone therapy, or surgery, can adversely impact reproductive function in both women men. The effects of treatment on sexes may lead to loss fertility, sexual desire function, deficiency, which results additional long-term morbidity more than a third patients. Given the importance most people, often devastating effect it, we propose proactive assessment functional endocrinological be made vital...